{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T04:48:40Z","timestamp":1774327720671,"version":"3.50.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T00:00:00Z","timestamp":1702944000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T00:00:00Z","timestamp":1702944000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1007\/s10147-023-02447-2","type":"journal-article","created":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T08:02:33Z","timestamp":1702972953000},"page":"205-212","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Comparative assessment of disease recurrence after transurethral resection of non-muscle-invasive bladder cancer with and without a photodynamic diagnosis using 5-aminolevulinic acid: a propensity score-matching analysis"],"prefix":"10.1007","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8159-9793","authenticated-orcid":false,"given":"Yuto","family":"Matsushita","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makito","family":"Miyake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobutaka","family":"Nishimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koshiro","family":"Nishimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideo","family":"Fukuhara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keita","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masafumi","family":"Oyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiji","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideyasu","family":"Matsuyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyohide","family":"Fujimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideaki","family":"Miyake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,12,19]]},"reference":[{"key":"2447_CR1","unstructured":"IARC, Cancer Today. (2022) Estimated number of new cases in 2020, worldwide, both sexes, all ages. 2021. https:\/\/gco.iarc.fr\/today\/online-analysis-table. Accessed Mar 2023"},{"key":"2447_CR2","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.eururo.2013.07.007","volume":"64","author":"M Rink","year":"2013","unstructured":"Rink M, Babjuk M, Catto JW et al (2013) Hexyl aminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: a critical review of the current literature. Eur Urol 64:624\u2013638","journal-title":"Eur Urol"},{"key":"2447_CR3","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.euros.2021.06.011","volume":"31","author":"R Veeratterapillay","year":"2021","unstructured":"Veeratterapillay R, Gravestock P, Nambiar A et al (2021) Time to turn on the blue lights: a systematic review and meta-analysis of photodynamic diagnosis for bladder cancer. Eur Urol Open Sci 31:17\u201327","journal-title":"Eur Urol Open Sci"},{"key":"2447_CR4","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1111\/bju.15723","volume":"130","author":"P Maisch","year":"2022","unstructured":"Maisch P, Koziarz A, Vajgrt J et al (2022) Blue vs white light for transurethral resection of non-muscle-invasive bladder cancer: an abridged Cochrane review. BJU Int 130:730\u2013740","journal-title":"BJU Int"},{"key":"2447_CR5","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.eururo.2009.10.030","volume":"57","author":"MC Schumacher","year":"2010","unstructured":"Schumacher MC, Holmang S, Davidsson T et al (2010) Transurethral resection of non-muscle-invasive bladder transitional cell cancers with or without 5-aminolevulinic acid under visible and fluorescent light: results of a prospective, randomised, multicentre study. Eur Urol 57:293\u2013299","journal-title":"Eur Urol"},{"key":"2447_CR6","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1002\/cncr.25523","volume":"117","author":"A Stenzl","year":"2011","unstructured":"Stenzl A, Penkoff H, Dajc-Sommerer E et al (2011) Detection and clinical outcome of urinary bladder cancer with 5-aminolevulinic acid-induced fluorescence cystoscopy: a multicenter randomized, double-blind, placebo-controlled trial. Cancer 117:938\u2013947","journal-title":"Cancer"},{"key":"2447_CR7","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1111\/bju.12355","volume":"112","author":"T O'Brien","year":"2013","unstructured":"O\u2019Brien T, Ray E, Chatterton K et al (2013) Prospective randomized trial of hexylaminolevulinate photodynamic-assisted transurethral resection of bladder tumour (TURBT) plus single-shot intravesical mitomycin C vs conventional white-light TURBT plus mitomycin C in newly presenting non-muscle-invasive bladder cancer. BJU Int 112:1096\u20131104","journal-title":"BJU Int"},{"key":"2447_CR8","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200092","author":"R Heer","year":"2022","unstructured":"Heer R, Lewis R, Vadiveloo T et al (2022) A randomized trial of PHOTOdynamic surgery in non\u2013muscle-invasive bladder cancer. NEJM Evidence. https:\/\/doi.org\/10.1056\/EVIDoa2200092","journal-title":"NEJM Evidence"},{"key":"2447_CR9","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1111\/iju.14099","volume":"26","author":"T Nohara","year":"2019","unstructured":"Nohara T, Kato Y, Nakano T et al (2019) Intraoperative hypotension caused by oral administration of 5-aminolevulinic acid for photodynamic diagnosis in patients with bladder cancer. Int J Urol 26:1064\u20131068","journal-title":"Int J Urol"},{"key":"2447_CR10","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1111\/iju.13856","volume":"26","author":"M Miyake","year":"2019","unstructured":"Miyake M, Nakai Y, Hori S et al (2019) Transient liver toxicity as a result of the oral administration of 5-aminolevulinic acid for photodynamic diagnosis in patients with bladder cancer. Int J Urol 26:315\u2013317","journal-title":"Int J Urol"},{"key":"2447_CR11","doi-asserted-by":"publisher","first-page":"2953","DOI":"10.1007\/s00345-020-03587-0","volume":"39","author":"T Todenhofer","year":"2021","unstructured":"Todenhofer T, Maas M, Ketz M et al (2021) Retrospective German claims data study on initial treatment of bladder carcinoma (BCa) by transurethral bladder resection (TURB): a comparative analysis of costs using standard white light- (WL-) vs. blue light- (BL-) TURB. World J Urol 39:2953\u20132960","journal-title":"World J Urol"},{"key":"2447_CR12","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1093\/jjco\/hyac203","volume":"53","author":"N Nishimura","year":"2023","unstructured":"Nishimura N, Miyake M, Miyamoto T et al (2023) The Japanese health care system-based cost-effectiveness of photodynamic diagnosis-assisted transurethral resection of bladder tumor for non-muscle invasive bladder cancer. Jpn J Clin Oncol 53:343\u2013348","journal-title":"Jpn J Clin Oncol"},{"key":"2447_CR13","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","volume":"81","author":"M Babjuk","year":"2022","unstructured":"Babjuk M, Burger M, Capoun O et al (2022) European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ). Eur Urol 81:75\u201394","journal-title":"Eur Urol"},{"key":"2447_CR14","unstructured":"Flaig TW, Spiess PE, Abern M et al (2023) NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Bladder Cancer V.1.2023"},{"key":"2447_CR15","doi-asserted-by":"publisher","first-page":"185","DOI":"10.3390\/diagnostics11020185","volume":"11","author":"M Miyake","year":"2021","unstructured":"Miyake M, Nishimura N, Nakai Y et al (2021) Photodynamic diagnosis-assisted transurethral resection using oral 5-aminolevulinic acid decreases the risk of repeated recurrence in non-muscle-invasive bladder cancer: a cumulative incidence analysis by the person-time method. Diagnostics (Basel) 11:185","journal-title":"Diagnostics (Basel)"},{"key":"2447_CR16","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.pdpdt.2015.12.011","volume":"13","author":"K Inoue","year":"2016","unstructured":"Inoue K, Matsuyama H, Fujimoto K et al (2016) The clinical trial on the safety and effectiveness of the photodynamic diagnosis of non-muscle-invasive bladder cancer using fluorescent light-guided cystoscopy after oral administration of 5-aminolevulinic acid (5-ALA). Photodiagnosis Photodyn Ther 13:91\u201396","journal-title":"Photodiagnosis Photodyn Ther"},{"key":"2447_CR17","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1111\/iju.13718","volume":"25","author":"Y Nakai","year":"2018","unstructured":"Nakai Y, Inoue K, Tsuzuki T et al (2018) Oral 5-aminolevulinic acid-mediated photodynamic diagnosis using fluorescence cystoscopy for non-muscle-invasive bladder cancer: a multicenter phase III study. Int J Urol 25:723\u2013729","journal-title":"Int J Urol"},{"key":"2447_CR18","doi-asserted-by":"publisher","first-page":"E297","DOI":"10.1111\/j.1464-410X.2011.10090.x","volume":"108","author":"GG Hermann","year":"2011","unstructured":"Hermann GG, Mogensen K, Carlsson S et al (2011) Fluorescence-guided transurethral resection of bladder tumours reduces bladder tumour recurrence due to less residual tumour tissue in Ta\/T1 patients: a randomized two-centre study. BJU Int 108:E297-303","journal-title":"BJU Int"},{"key":"2447_CR19","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1111\/j.1464-410X.2011.10374.x","volume":"109","author":"B Geavlete","year":"2012","unstructured":"Geavlete B, Multescu R, Georgescu D et al (2012) Treatment changes and long-term recurrence rates after hexaminolevulinate (HAL) fluorescence cystoscopy: does it really make a difference in patients with non-muscle-invasive bladder cancer (NMIBC)? BJU Int 109:549\u2013556","journal-title":"BJU Int"},{"key":"2447_CR20","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1007\/s11255-013-0603-z","volume":"46","author":"P Gkritsios","year":"2014","unstructured":"Gkritsios P, Hatzimouratidis K, Kazantzidis S et al (2014) Hexaminolevulinate-guided transurethral resection of non-muscle-invasive bladder cancer does not reduce the recurrence rates after a 2-year follow-up: a prospective randomized trial. Int Urol Nephrol 46:927\u2013933","journal-title":"Int Urol Nephrol"},{"key":"2447_CR21","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1007\/s00345-016-1927-y","volume":"35","author":"AI Rolevich","year":"2017","unstructured":"Rolevich AI, Zhegalik AG, Mokhort AA et al (2017) Results of a prospective randomized study assessing the efficacy of fluorescent cystoscopy-assisted transurethral resection and single instillation of doxorubicin in patients with non-muscle-invasive bladder cancer. World J Urol 35:745\u2013752","journal-title":"World J Urol"},{"key":"2447_CR22","doi-asserted-by":"publisher","first-page":"102179","DOI":"10.1016\/j.pdpdt.2021.102179","volume":"33","author":"J Miyakawa","year":"2021","unstructured":"Miyakawa J, Kawai T, Makino K et al (2021) Impact of age, body mass index, and renal function for severe hypotension caused by oral 5-aminolevulinic acid administration in patients undergoing transurethral resection of bladder tumor. Photodiagnosis Photodyn Ther 33:102179","journal-title":"Photodiagnosis Photodyn Ther"},{"key":"2447_CR23","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1186\/s12885-021-08976-1","volume":"21","author":"H Fukuhara","year":"2021","unstructured":"Fukuhara H, Nohara T, Nishimoto K et al (2021) Identification of risk factors associated with oral 5-aminolevulinic acid-induced hypotension in photodynamic diagnosis for non-muscle invasive bladder cancer: a multicenter retrospective study. BMC Cancer 21:1223","journal-title":"BMC Cancer"},{"key":"2447_CR24","unstructured":"Aminolevulinic acid hydrochloride, known as ALA HCl (Gleolan, NX Development Corp.) as an optical imaging agent indicated in patients with gliomas (2017). https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/aminolevulinic-acid-hydrochloride-known-ala-hcl-gleolan-nx-development-corp-optical-imaging-agent. Accessed Jul 2023"},{"key":"2447_CR25","doi-asserted-by":"publisher","first-page":"103294","DOI":"10.1016\/j.pdpdt.2023.103294","volume":"41","author":"K Kobayashi","year":"2023","unstructured":"Kobayashi K, Matsuyama H, Oka S et al (2023) Risks and benefits of transurethral resection of the bladder tumor using photodynamic diagnosis with oral 5-aminolevulinic acid hydrochloride according to age and history of recurrence in patients with non-muscle invasive bladder cancer. Photodiagnosis Photodyn Ther 41:103294","journal-title":"Photodiagnosis Photodyn Ther"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-023-02447-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-023-02447-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-023-02447-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T03:06:30Z","timestamp":1706151990000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-023-02447-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,19]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["2447"],"URL":"https:\/\/doi.org\/10.1007\/s10147-023-02447-2","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,19]]},"assertion":[{"value":"13 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Hideyasu Matsuyama received lecture fees from Nippon Kayaku Co.,Ltd; the other authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}